Detecting inflammatory diseases
OUR VISION
To provide affordable and effective diagnostics around the world
OUR MISSION
To develop and manufacture medical devices for early and reliable diagnosis of inflammatory diseases
Welcome to IDxSense, a trailblazer in the life sciences sector.
We are at the forefront of designing, developing, and manufacturing in vitro diagnostic devices, targeting markets with significant unmet medical needs. Our passion lies in creating chemical probes that accurately and efficiently detect key biomarkers of inflammatory diseases.
Diagnostics have revolutionised healthcare, serving as a powerful tool for early detection of diseases and monitoring treatment responses. They play a crucial role in every step of a patient’s journey, from early detection and disease screening to monitoring treatment responses, offering a path to improved health outcomes.
At IDxSense, we are committed to harnessing this potential to significantly enhance health outcomes. Our innovative technology and expertise in the field enable us to provide our customers with high-quality products that assist healthcare professionals in making informed decisions in diagnosis and treatment. Join us on our mission to transform patient care through innovation in diagnostics.
Join us on our mission to transform patient care through innovation in diagnostics.
A world where science meets healthcare for the betterment of all.
TECHNOLOGY
At IDxSense, we are at the cutting edge of biotechnology, with a primary focus on designing fluorescent probes that target key biomarkers in inflammation.
INDICATIONS
The IDxSense platform consists of diagnostic testing tools for tissues, blood, urine and/or stool among other clinical samples.
The IDxSense Team
“Diagnostic tests are increasingly important around the world as a first defence against the spread of many diseases”
WHO
“70% of clinical decisions are based on IVD tests”
BIVDA
“Diagnosis is a driver of patient, financial and health systems impact, and a critical enabler of universal health coverage”
WHO